



Breakout Session 2.1: Metastatic ILC

Adrian Lee, Amanda Fitzpatrick, Christine Desmedt, Christine McKay, Jose Sandoval, Julia Katherine Levine, Rachel Jankowitz



1. Enhance research on liquid biopsies for patients with ILC

Prioritize focused research on the application of liquid biopsies **specifically for patients diagnosed with ILC**, addressing the unique characteristics of this breast cancer subtype.

2. Investigate the clinical utility of liquid biopsies in various biofluids

Conduct research on the clinical effectiveness of **liquid biopsies** in **biofluids beyond blood**, such as cerebrospinal fluid, pleural effusion, and ascites, particularly in relation to the common metastatic sites seen in ILC.



3. Increase awareness of the uniqueness of ILC

Raise **awareness** among **clinicians, researchers, and patients** about the distinct **biology** and **clinical course** of ILC, including the unanswered questions surrounding its **diagnosis, treatment** options, and **long-term follow-up**.



4. Promote research on misdiagnosis and delayed diagnosis in ILC

Support initiatives that **investigate** the prevalence, causes and consequences of **misdiagnosis or delayed diagnosis** of ILC, as these are critical issues frequently highlighted by patients and can have significant impacts on outcomes.

5. Address patient-identified concerns through targeted research

Incorporate **patient-reported concerns**, such as delayed diagnosis, treatment uncertainties, and follow-up difficulties, into research priorities to ensure that the **issues most relevant to the patients** are thoroughly explored.